Followers | 1 |
Posts | 55 |
Boards Moderated | 0 |
Alias Born | 05/02/2021 |
Thursday, May 25, 2023 12:24:02 PM
Soon there will be no room for shorts ....
Recent OCGN News
- Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 • GlobeNewswire Inc. • 10/28/2024 10:30:00 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/22/2024 10:06:47 PM
- Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease • GlobeNewswire Inc. • 10/22/2024 11:02:15 AM
- Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 10/17/2024 11:30:11 AM
- Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial • GlobeNewswire Inc. • 10/09/2024 10:30:32 AM
- Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa • GlobeNewswire Inc. • 10/02/2024 10:30:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/26/2024 08:27:41 PM
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 09/24/2024 11:30:00 AM
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop • GlobeNewswire Inc. • 09/09/2024 10:30:12 AM
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit • GlobeNewswire Inc. • 09/05/2024 11:00:07 AM
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:30:42 AM
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 08/28/2024 10:30:32 AM
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 08/26/2024 11:02:41 AM
- Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading • PR Newswire (US) • 08/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/16/2024 08:16:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:00:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 05:03:56 PM
- Ocugen Provides Business Update with Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:06:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:18:41 AM
- Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa • GlobeNewswire Inc. • 08/05/2024 10:30:33 AM
- Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock • GlobeNewswire Inc. • 08/02/2024 07:22:33 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 01:18:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 01:16:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM